New advances in prevention of migraine

References

1. ↵
   1. Smitherman TA,
   2. Burch R,
   3. Sheikh H,
   4. Loder E

   (2013) The prevalence, impact, and treatment of migraine and severe headaches in the United States:a review of statistics from national surveillance studies. Headache 53, 427–436.
2. ↵
   1. Benamer HT,
   2. Deleu D,
   3. Grosset D

   (2010) Epidemiology of headache in Arab countries. J Headache Pain 11, 1–3.
3. ↵
   1. Headache Classification Committee of the International Headache Society (IHS)

   (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33, 629–808.
4. ↵
   1. Lanteri-Minet M,
   2. Valade D,
   3. Geraud G,
   4. Lucas C,
   5. Donnet A

   (2014) Revised French guidelines for the diagnosis and management of migraine in adults and children. J Headache Pain 15, 2.
5. ↵
   1. Robbins L,
   2. Bassett B

   (2012) Migraine Treatment from A to Z. Pract Pain Manag, 66–79.
6. ↵
   1. NICE

   (2012) Headaches:Diagnosis and management of headaches in young people and adults. National Institute for Health and Care Excellence, 1–29.
7. ↵
   1. Lipton RB,
   2. Silberstein SD

   (2015) Episodic and chronic migraine headache:breaking down barriers to optimal treatment and prevention. Headache 55, 103–122.
8. ↵
   1. Olesen J,
   2. Ashina M

   (2011) Emerging migraine treatments and drug targets. Trends Pharmacol Sci 32, 352–359.
9. 1. Hazard E,
   2. Munakata J,
   3. Bigal ME,
   4. Rupnow MF,
   5. Lipton RB

   (2009) The burden of migraine in the United States:current and emerging perspectives on disease management and economic analysis. Value Health 12, 55–64.
10. ↵
    1. Stovner LJ,
    2. Andrée C

    (2008) Impact of headache in Europe:a review for the Eurolight project. J Headache Pain 9, 139–146.
11. ↵
    1. Diener H,
    2. Solbach K,
    3. Holle D,
    4. Gaul C

    (2015) Integrated care for chronic migraine patients:epidemiology, burden, diagnosis and treatment options. Clin Med (Lond) 15, 344–50.
12. ↵
    1. Estemalik E,
    2. Tepper S

    (2013) Preventive treatment in migraine and the new US guidelines. Neuropsychiatr Dis Treat 9, 709–720.
13. ↵
    1. Silberstein SD,
    2. Holland S,
    3. Freitag F,
    4. Dodick DW,
    5. Argoff C,
    6. Ashman E

    (2012) Evidence-based guideline update:pharmacologic treatment for episodic migraine prevention in adults:report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 78, 1337–1345.
14. ↵
    1. Shapiro RE

    (2012) Preventive treatment of migraine. Headache 52, 65–9.
15. ↵
    1. Pringsheim T,
    2. Davenport W,
    3. Mackie G,
    4. Worthington I,
    5. Aubé M,
    6. Christie SN,
    7. et al.

    (2012) Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci 39, S1–59.
16. ↵
    1. Apostol G,
    2. Pakalnis A,
    3. Laforet GA,
    4. Robieson WZ,
    5. Olson E,
    6. Abi-Saab WM,
    7. et al.

    (2009) Safety and tolerability of divalproex sodium extended-release in the prophylaxis of migraine headaches:results of an open-label extension trial in adolescents. Headache 49, 36–44.
17. ↵
    1. Ashtari F,
    2. Shaygannejad V,
    3. Akbari M

    (2008) A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand 118, 301–305.
18. ↵
    1. Apostol G,
    2. Pakalnis A,
    3. Laforet GA,
    4. Robieson WZ,
    5. Olson E,
    6. Abi-Saab WM,
    7. et al.

    (2009) Safety and tolerability of divalproex sodium extended-release in the prophylaxis of migraine headaches:results of an open-label extension trial in adolescents. Headache 49, 36–44.
19. ↵
    1. Loder E,
    2. Burch R,
    3. Rizzoli P

    (2012) The 2012 AHS/AAN guidelines for prevention of episodic migraine:a summary and comparison with other recent clinical practice guidelines. Headache 52, 930–945.
20. ↵
    1. Shapiro RE

    (2012) Preventive treatment of migraine. Headache 52, 65–69.
21. ↵
    1. Holland S,
    2. Silberstein SD,
    3. Freitag F,
    4. Dodick DW,
    5. Argoff C,
    6. Ashman E

    (2012) Evidence-based guideline update:NSAIDs and other complementary treatments for episodic migraine prevention in adults:report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 78, 1346–1353.
22. ↵
    1. Sumelahti ML,
    2. Mattila K,
    3. Sillanmäki L,
    4. Sumanen M

    (2011) Prescription patterns in preventive and abortive migraine medication. Cephalalgia 31, 1659–1663.
23. ↵
    1. Deaton TL,
    2. Mauro LS

    (2014) Topiramate for migraine prophylaxis in pediatric patients. Ann Pharmacother 48, 638–643.
24. ↵
    1. Kacperski J,
    2. Hershey AD

    (2014) Preventive drugs in childhood and adolescent migraine. Curr Pain Headache Rep 18, 422.
25. ↵
    1. Evers S,
    2. Afra J,
    3. Frese A,
    4. Goadsby PJ,
    5. Linde M,
    6. May A,
    7. et al.

    (2009) EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol 16, 968–981.
26. ↵
    1. Catamaran

    (2013) Spotlight on drugs in the pharmaceutical pipeline:agents for migraine. Catamaran RxOutlook 7, 1–4.
27. ↵
    1. Ashkenazi A,
    2. Blumenfeld A

    (2013) OnabotulinumtoxinA for the treatment of headache. Headache 53, Suppl 2, 54–61.
28. ↵
    1. Klein MM,
    2. Treister R,
    3. Raij T,
    4. Pascual-Leone A,
    5. Park L,
    6. Nurmikko T,
    7. et al.

    (2015) Transcranial magnetic stimulation of the brain:guidelines for pain treatment research. Pain 156, 1601–1614.